Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

This Phase II trial is testing enfortumab vedotin — an antibody-drug conjugate (a targeted drug that delivers chemotherapy directly to cancer cells) — in patients with advanced or metastatic colorectal cancer (CRC) or liver cancer (hepatocellular carcinoma, HCC) whose cancer has progressed after standard treatments. **You may be eligible if...** - You are 18 or older with confirmed advanced colorectal cancer or liver cancer - For CRC: your cancer progressed after 2-3 prior treatment lines including standard chemotherapy drugs - For HCC: your cancer progressed after 1-2 prior treatment lines including immunotherapy or targeted therapy - You are in good health (ECOG ≤1) with adequate blood, liver, and kidney function **You may NOT be eligible if...** - You have active brain metastases requiring steroids - You have previously received enfortumab vedotin or another MMAE-based drug - You have another cancer diagnosed within the last 3 years (with some exceptions) - You have HIV, active hepatitis B or C, significant heart disease, or uncontrolled diabetes - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.